Acasti Pharma, Inc (ACST)

[I.B.Broke]

Acasti Expands Global Patent Portfolio with Newly Granted Patents in South Korea and Canada

LAVAL, QUÉBEC--(Marketwired - Jan. 4, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), an emerging biopharmaceutical company focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced the granting of a patent by the South Korean Patent Office and the granting of a corresponding patent by the Canadian Intellectual Property Office, further strengthening the international intellectual property position of CaPre.
The granted patents are valid until 2030 and relate to a concentrated phospholipid composition and method of using same for treating or preventing disorders associated with cardiovascular diseases. These patents add to Acasti's growing portfolio of issued patents in the United States, Taiwan, Australia, China, Japan, Mexico and Panama. Patent applications with similar claims are being pursued in several other jurisdictions.
"The granting of these additional patents further increase the global commercial opportunities for CaPre," highlighted Pierre Lemieux, Ph.D, Acasti's chief operating officer. "Both patents strengthen the competitive barriers for CaPre and provide market access to the Canadian and South Korean pharmaceutical territories, both of which have strong commercial potential for CaPre."

http://www.marketwired.com/press-release/acasti-expands-global-patent-portfolio-with-newly-granted-patents-south-korea-canada-tsx-venture-acst-2244080.htm